Key result
Antihypertensive therapy with enalapril for 8 months induced regression of left ventricular hypertrophy without altering myocardial reflectivity, suggesting proportionate regression of tissue components.
Why the study?
Does enalapril therapy affect ultrasonic myocardial reflectivity in patients with essential hypertension and left ventricular hypertrophy?
Observational (n=19)
No
Does enalapril therapy affect ultrasonic myocardial reflectivity in patients with essential hypertension and left ventricular hypertrophy?
Regression of hypertensive left ventricular hypertrophy with enalapril does not alter myocardial reflectivity, suggesting proportionate reduction of myocyte and connective tissue.
Enalapril-associated LVH regression was not accompanied by reflectivity changes; hypothesis-generating for proportionate tissue effects, needs randomized confirmation.
OBJECTIVE: Ultrasonic backscatter from the myocardial walls is directly related to the morphometrically or biochemically evaluated collagen content in man, and shows a normal pattern of quantitatively assessed ultrasonic backscatter in hypertensive patients, even in the presence of left ventricular hypertrophy. Whether the pharmacologically induced regression of left ventricular hypertrophy in hypertensive patients is accompanied by a disproportionate increase in relative connective tissue content is not yet known. The objective of the present study was to assess the effects of regression of left ventricular hypertrophy on the quantitatively evaluated myocardial reflectivity in essential hypertensives. DESIGN: We evaluated 19 mild-to-moderate essential hypertensives with echocardiographically assessed left ventricular hypertrophy, before and after 8 months' effective antihypertensive therapy with 20-40 mg enalapril once a day, associated with diuretics or calcium antagonists, or both, in six patients to achieve optimal blood pressure control. Using a modified echo machine developed in the Institute of Clinical Physiology, Pisa, an on-line radio-frequency analysis was performed to obtain quantitative operator-independent measurements of the integrated backscatter signal of the ventricular septum and the posterior wall. The integrated values of the radio-frequency signal from the myocardial walls were normalized for those from the pericardial interface and were expressed as percentages (integrated backscatter index). RESULTS: In comparison with baseline, the treated hypertensives showed significant decreases in mean blood pressure, left ventricular mass index, and septal and posterior wall thickness. However, integrated backscatter index values were similar at baseline and after therapy for both the septum and the posterior wall. CONCLUSION: Antihypertensive therapy with enalapril does not increase myocardial reflectivity, although it does induce regression of left ventricular hypertrophy. This suggests that, in accord with experimental data, regression of hypertrophy is achieved by enalapril through a proportionate regression of the myocyte and connective tissue components of the myocardium.
No takes yet. Share an insight, caveat, or question.
Lucarini et al. (1994) conducted an observational in Essential hypertension with left ventricular hypertrophy (n=19). Enalapril vs. Baseline was evaluated on Integrated backscatter index of the ventricular septum and posterior wall. Antihypertensive therapy with enalapril for 8 months induced regression of left ventricular hypertrophy without altering myocardial reflectivity, suggesting proportionate regression of tissue components.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: